Novitas says Pacific Edge’s CxBladder tests are ‘not payable’

Novitas says Pacific Edge’s CxBladder tests are ‘not payable’
The company can continue to apply for renewed coverage. (Image: Pacific Edge)
Rebecca Howard
The long-awaited draft Local Coverage Determination from Novitas is not good news for Pacific Edge’s US business. According to the determination (LCD), “CxBladder tests are not reasonable and necessary to support positive outcomes in the management of bladder cancer and, therefore, are not payable”.In June 2023, Pacific Edge confirmed that the LCD from Novitas — its Medicare administrative contractor — meant its flagship Cxbladder test for bladder cancer didn’t meet the threshold required for coverage un...

More Markets

NZ sharemarket drops as US market rallies
Markets Market Close

NZ sharemarket drops as US market rallies

The S&P/NZX 50 Index closed down 1.02% or 122.14 points.

Tom Raynel 30 Apr 2025
Radius buys care home off Arvida
Property

Radius buys care home off Arvida

Radius Care will have another 109 beds in Christchurch.

Gregor Thompson 30 Apr 2025
Airports v airlines and the regional monopoly conundrum
Policy Analysis

Airports v airlines and the regional monopoly conundrum

Why is airport regulation being reviewed when all the fuss is about airfares? 

Pattrick Smellie 30 Apr 2025
‘It really is upwards from here,’ Pacific Edge CEO
Markets

‘It really is upwards from here,’ Pacific Edge CEO

The AUA’s guideline has made Pacific Edge’s tests a talking point. 

Rebecca Howard 30 Apr 2025